The global biliary stents market was valued at USD 162.1 million in 2026 and is estimated to reach USD 168.58 million in 2027, with a projected value of USD 257.82 million by 2036, reflecting a 4.75% CAGR from 2027–2036. Within this market, metal stents are gaining strategic importance because their longer patency and durability can reduce the frequency of repeat interventions. This is particularly relevant in the management of biliary obstruction, where maintaining drainage over a sustained period can improve procedural efficiency and reduce the need for repeated treatment.

The momentum behind metal stents is also connected to advances in self-expanding and drug-eluting technologies. Improvements in stent design are expanding their suitability for both malignant and non-neoplastic biliary obstructions. For healthcare providers, this creates an opportunity to focus not only on device placement but also on longer-term procedural outcomes, reliability, and patient management.

Another important structural shift is the growing role of Ambulatory Surgical Centers (ASCs). As minimally invasive biliary procedures increasingly move toward outpatient environments, stent technologies that support streamlined workflows and efficient treatment pathways may become more relevant. This transition can influence purchasing decaisions, with providers increasingly considering device performance alongside procedural efficiency.

Overall, the market is moving toward technologies that can combine durability, minimally invasive deployment, and improved clinical workflow. This creates opportunities for manufacturers to differentiate through product design, delivery systems, and technologies that address specific biliary intervention requirements.

Regional Analysis — North America Leads While Asia Pacific Builds Momentum

North America maintains a leading position in the biliary stents market, supported by established endoscopy infrastructure, broad availability of minimally invasive biliary procedures, and specialist expertise across hospitals and gastroenterology centers. The region's mature healthcare ecosystem provides manufacturers with an established environment for adoption of advanced stenting technologies.

The opportunity in North America is therefore less dependent on basic infrastructure development and more closely associated with technology advancement and procedural optimization. Hospitals and specialist centers can increasingly evaluate stents according to durability, clinical utility, deployment characteristics, and their ability to support efficient intervention.

Asia Pacific presents a different market dynamic. The region is projected to grow at a 5.88% CAGR, supported by expanding hospital capabilities, increasing access to endoscopic interventions, and greater adoption of gastrointestinal and hepatobiliary care.

The contrast between the two regions highlights two distinct commercial strategies:

• North America: Greater emphasis on advanced technologies, specialist procedures, and established clinical networks.
• Asia Pacific: Greater opportunity from healthcare infrastructure expansion and increasing access to endoscopic treatment.
• Manufacturers: Localization of distribution, training, and clinical support can be particularly important when entering developing procedural markets.
• Healthcare providers: Growing availability of minimally invasive treatment can expand the addressable patient population.

The regional landscape therefore combines a mature technology market in North America with an infrastructure- and access-driven growth opportunity across Asia Pacific.

Industry Challenge — Expanding Adoption Requires More Than Device Innovation

One of the central challenges for the biliary stents industry is ensuring that technological advances translate into consistent clinical adoption. Biliary interventions require specialized expertise, appropriate endoscopic infrastructure, and experienced healthcare professionals. Consequently, the availability of an advanced stent alone does not guarantee widespread utilization.

The increasing prevalence of biliary disorders and chronic liver diseases is creating demand for interventional treatment, but healthcare systems must also have the capacity to deliver these procedures. This makes specialist availability and endoscopy infrastructure important commercial considerations.

Another challenge is balancing device durability with the requirements of individual clinical applications. Different biliary obstructions can require different stent characteristics, and physicians may consider factors such as deployment, patency, removability, and procedural complexity when selecting a device.

The industry's expansion into ASCs introduces an additional operational consideration. Outpatient settings prioritize efficient workflows and shorter stays, meaning stent systems need to fit smoothly into streamlined procedural pathways.

For manufacturers, this environment places greater importance on the broader value proposition surrounding a device. Product development may increasingly need to be supported by physician education, procedural training, distribution capabilities, and evidence demonstrating practical clinical utility.

Product & Segment Comparison — Metal Versus Polymer Stents

Metal and polymer stents represent two important approaches within biliary intervention, with each offering different characteristics and potential applications.

Factor	Metal Stents	Polymer Stents
Primary characteristic	Longer patency and durability	Flexible approach for selected biliary applications
Replacement considerations	Potential to reduce replacement frequency	May require different management depending on clinical use
Market position	Core revenue segment	Emerging opportunity segment
Strategic relevance	Strong focus on sustained biliary drainage	Opportunity for product innovation and application-specific solutions
Provider consideration	Procedural efficiency and durability	Clinical suitability and application requirements

Metal stents currently represent the core revenue segment because their durability and longer patency can support sustained management of biliary obstruction. Their characteristics are particularly relevant where minimizing repeat interventions is an important consideration.

Polymer stents, meanwhile, represent an emerging opportunity. Their future market potential can be linked to application-specific requirements and continued product development. Rather than viewing the two categories as direct substitutes in every clinical situation, manufacturers can address different procedural needs through differentiated product portfolios.

This creates room for companies to develop complementary product strategies rather than relying exclusively on a single stent material. The competitive opportunity increasingly lies in matching stent characteristics with the clinical setting, obstruction type, and procedural workflow.

Geographic Opportunity — Markets With Strategic Relevance

United States

The United States represents an important market because of its established endoscopy ecosystem, specialist availability, and broad use of minimally invasive biliary procedures. The market is also relevant for companies seeking commercial validation and access to advanced therapeutic endoscopy networks.

Japan

Japan offers strategic relevance because of its sophisticated healthcare system and established medical-device environment. The approval of CGBIO's ARISTENT biliary stents by Japan's Pharmaceuticals and Medical Devices Agency demonstrates the importance of Japan as a market for companies pursuing international expansion.

South Korea

South Korea is relevant both as a healthcare market and as a source of biliary stent innovation. TaeWoong Medical's expansion of its portfolio demonstrates the potential for Korean manufacturers to participate in international competition through advanced self-expanding technologies.

China

China represents a significant strategic opportunity within Asia Pacific as healthcare capabilities and access to endoscopic interventions continue to expand. The presence of Micro-Tech (Nanjing) within the competitive landscape also illustrates the role of Chinese companies in the broader biliary stents industry.

Across these markets, successful expansion is likely to depend on regulatory execution, distribution capabilities, physician familiarity, and the ability to align products with local procedural practices.

Competitive Landscape — Companies Are Expanding Through Product and Distribution Strategies

Competition in the biliary stents market includes global medical-device companies as well as specialized regional manufacturers. Key participants include Boston Scientific Corporation, Cook Medical, Olympus Corporation, Becton, Dickinson and Company, Medtronic, Teleflex, ConMed Corporation, TaeWoong Medical, Merit Medical Systems, and Micro-Tech (Nanjing).

The competitive landscape indicates that market participation is not being driven by a single strategy. Large medical-device companies can leverage established distribution networks and broader endoscopy portfolios, while specialized manufacturers can differentiate through focused biliary technologies.

Recent corporate activity also highlights the importance of commercial access. Olympus Corporation's transition involving the GORE VIABIL Biliary Endoprosthesis demonstrates how distribution and portfolio integration can strengthen market reach. By incorporating an established biliary product into its endotherapy sales network, Olympus expanded the commercial relevance of its existing infrastructure.

At the same time, TaeWoong Medical's regulatory progress in the United States illustrates the importance of product-level innovation and geographic expansion. CGBIO's regulatory achievement in Japan similarly demonstrates how market-entry approvals can support international growth strategies.

The broader competitive direction suggests increasing emphasis on portfolio expansion, regulatory approvals, distribution networks, and minimally invasive technologies rather than competition based solely on individual stent products

Recent Industry News — Regulatory Approvals and Commercial Expansion Shape the Market

CGBIO — July 2024

In July 2024, CGBIO received product approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its ARISTENT biliary stents. The approval supported the company's entry into the Japanese market and strengthened its international expansion strategy.

The development demonstrates how regulatory approvals can function as important growth gateways for specialized medical-device companies. Entry into established healthcare markets can also provide manufacturers with opportunities to develop regional distribution and commercial partnerships.

Olympus Corporation — December 2025

In December 2025, Olympus Corporation, W. L. Gore & Associates, and ConMed Corporation announced a transition in commercial support for the GORE VIABIL Biliary Endoprosthesis. Olympus assumed U.S. distribution responsibilities and integrated the stent into its established endotherapy sales network.

The development highlights the growing importance of commercial infrastructure in the biliary stents industry. Rather than relying exclusively on new product development, companies can strengthen their market position by using established sales and distribution capabilities to expand access to existing technologies.

TaeWoong Medical — May 2026

In May 2026, TaeWoong Medical USA received U.S. FDA 510(k) clearance for the Niti-S SPAXUS Stent. The fully covered, self-expanding metallic stent is designed for EUS-guided procedures, supporting the company's U.S. commercial expansion and broadening its portfolio for minimally invasive biliary drainage and therapeutic endoscopy.

This development reflects the industry's movement toward specialized technologies for advanced minimally invasive procedures. It also demonstrates how regulatory clearance can enable regional expansion while allowing manufacturers to target evolving procedural approaches.

Taken together, these developments point to a market increasingly shaped by regulatory access, international expansion, distribution capabilities, and advanced endoscopic technologies.

Read more about this report @ https://www.fundamentalbusinessinsights.com/industry-report/biliary-stents-market-3110

About Fundamental Business Insights:

Fundamental Business Insights is global market research and consulting company which is engaged in providing in depth market reports to its various types of clients like industrial sectors, financial sectors, universities, non-profit, and corporations. Our goal is to offer the correct information to the right stakeholder at the right time, in a format that enables logical and informed decision making. We have a team of consultants who have experience in offering executive level blueprints of markets and solutions. Our services include syndicated market studies, customized research reports, and consultation.

Contact us:
Robbin Fernandez
Head of Business Development
Fundamental Business Insights and Consulting
Email:  sales@fundamentalbusinessinsights.com

Read This Report in Regional Languages - 

https://www.fundamentalbusinessinsights.com/ko/industry-report/biliary-stents-market-3110

https://www.fundamentalbusinessinsights.com/ja/industry-report/biliary-stents-market-3110

https://www.fundamentalbusinessinsights.com/de/industry-report/biliary-stents-market-3110

https://www.fundamentalbusinessinsights.com/it/industry-report/biliary-stents-market-3110

https://www.fundamentalbusinessinsights.com/es/industry-report/biliary-stents-market-3110

https://www.fundamentalbusinessinsights.com/fr/industry-report/biliary-stents-market-3110